Your browser doesn't support javascript.
loading
[Effects of the MMR vaccination on the epidemiology of mumps in Germany]. / Effekte der Masern-Mumps-Röteln (MMR)-Impfung auf die Epidemiologie von Mumps in Deutschland.
Koch, J; Takla, A.
Afiliação
  • Koch J; Abteilung für Infektionsepidemiologie, Fachgebiet 33 Impfprävention, Robert Koch-Institut, DGZ-Ring 1, 13086, Berlin, Deutschland. kochj@rki.de
Article em De | MEDLINE | ID: mdl-23990094
Mumps is an acute viral infectious disease characterized by fever and swelling and tenderness of one or more salivary glands, usually the parotid gland. Since 1976, the German Standing Committee on Vaccination (STIKO) has recommended a mumps vaccination as part of the routine immunization schedule in former West Germany. In East Germany, the vaccination was only introduced in 1991 after reunification. In the preceding decades, no comprehensive surveillance system existed in Germany. However, for East Germany and the successional federal states of former East Germany, data on mumps incidence are available from different Eastern surveillance systems for the time period 1968-2012. According to these data, the incidence of mumps has dropped from > 200 cases/100,000 annually in the pre-vaccine era to currently <1/100,000. Recently, an age shift has been noted predominantly in the Western federal states. Based on data from school entry examinations and seroprevalence studies, the age shift is likely due to insufficient vaccination coverage and secondary vaccine failure ("waning immunity"). In view of the changes in mumps epidemiology and the increase of outbreaks among adolescents and young adults, the implementation of a nationwide mandatory notification was initiated and came into effect in March 2013. Mandatory notification enables the early detection of outbreaks and obtainment of comprehensive data for evaluation of the immunization program in place. Regarding the long-term prevention of mumps in Germany, it is hoped that--as part of the measles and rubella elimination effort--coverage rates for the second MMR dose among children will increase nationwide above 95% and existing vaccination gaps among adults will be closed.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação em Massa / Doenças Endêmicas / Vacina contra Sarampo-Caxumba-Rubéola / Erradicação de Doenças / Caxumba Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: De Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinação em Massa / Doenças Endêmicas / Vacina contra Sarampo-Caxumba-Rubéola / Erradicação de Doenças / Caxumba Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: De Ano de publicação: 2013 Tipo de documento: Article